The estimated Net Worth of John Poyhonen is at least $4.72 million dollars as of 13 April 2023. Mr. Poyhonen owns over 5,814 units of Heron Therapeutics Inc stock worth over $88,075 and over the last 10 years he sold HRTX stock worth over $0. In addition, he makes $4,632,310 as President and Chief Commercial Officer at Heron Therapeutics Inc.
John has made over 14 trades of the Heron Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 5,814 units of HRTX stock worth $10,523 on 13 April 2023.
The largest trade he's ever made was buying 50,000 units of Heron Therapeutics Inc stock on 22 March 2017 worth over $49,000. On average, John trades about 3,485 units every 73 days since 2014. As of 13 April 2023 he still owns at least 48,660 units of Heron Therapeutics Inc stock.
You can see the complete history of Mr. Poyhonen stock trades at the bottom of the page.
John W. Poyhonen serves as President and Chief Commercial Officer of the Company. Mr. Poyhonen was appointed Executive Vice President, Chief Commercial Officer in July 2019. He has more than 25 years of experience serving in leadership positions in biotechnology and pharmaceutical companies and commercializing innovative products. From 2014 through its acquisition by Firmenich, Inc. in November 2018, Mr. Poyhonen was the President, Chief Executive Officer and a director of Senomyx, Inc. He joined Senomyx, Inc. in 2003 as Vice President and Chief Business Officer; was promoted in 2004 to Vice President and Chief Financial and Business Officer; was named Senior Vice President, Chief Financial and Business Officer in 2006; was promoted to President and Chief Operating Officer in 2009; and promoted to President and Chief Executive Officer in 2014. From 1996 to 2003, Mr. Poyhonen served in various sales and marketing positions for Agouron Pharmaceuticals, Inc., most recently as Vice President of National Sales. Prior to holding this position, he served as Vice President of Marketing and Vice President of National Accounts. Mr. Poyhonen was previously a director of Ardea Biosciences, Inc. from 2007 through its acquisition by AstraZeneca PLC in 2012. He received a B.A. degree in marketing from Michigan State University and an M.B.A. degree from the University of Kansas.
As the President and Chief Commercial Officer of Heron Therapeutics Inc, the total compensation of John Poyhonen at Heron Therapeutics Inc is $4,632,310. There are 1 executives at Heron Therapeutics Inc getting paid more, with Barry Quart having the highest compensation of $5,870,480.
John Poyhonen is 60, he's been the President and Chief Commercial Officer of Heron Therapeutics Inc since 2020. There are 6 older and 14 younger executives at Heron Therapeutics Inc. The oldest executive at Heron Therapeutics Inc is Dr. Barry D. Quart, 64, who is the Chairman & CEO.
John's mailing address filed with the SEC is 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Heron Therapeutics Inc have traded over $96,663,574 worth of Heron Therapeutics Inc stock and bought 6,549,746 units worth $56,275,132 . The most active insiders traders include Kevin Ctang Capital Managem..., Adam Morgan et Craig A Collard. On average, Heron Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $176,989. The most recent stock trade was executed by Craig A Collard on 19 July 2024, trading 13,797 units of HRTX stock currently worth $24,973.
heron therapeutics, inc. (formerly a.p. pharma, inc.) is a specialty pharmaceutical company developing products using its proprietary biochronomer™ polymer-based drug delivery platform. this drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.
Heron Therapeutics Inc executives and other stock owners filed with the SEC include: